Comparative Pharmacology
Head-to-head clinical analysis: LEVOXYL versus LIOTHYRONINE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOXYL versus LIOTHYRONINE SODIUM.
LEVOXYL vs LIOTHYRONINE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levothyroxine is a synthetic thyroid hormone (T4) that is deiodinated to triiodothyronine (T3) in peripheral tissues, binding to thyroid hormone receptors in the nucleus and increasing metabolic rate, protein synthesis, and oxygen consumption.
Liothyronine is a synthetic form of triiodothyronine (T3), the active thyroid hormone. It binds to thyroid hormone receptors in the nucleus, modulating gene transcription and increasing basal metabolic rate, oxygen consumption, and thermogenesis. It enhances carbohydrate and lipid metabolism, and promotes normal growth and development.
Initial adult dose: 25-50 mcg orally once daily; titrate by 12.5-25 mcg every 6-8 weeks based on TSH. Maintenance dose: 50-200 mcg orally once daily.
25-75 mcg orally once daily; initial dose 25 mcg daily, titrate by 12.5-25 mcg increments every 1-2 weeks based on response.
None Documented
None Documented
6-7 days in euthyroid patients; prolonged in hypothyroidism (9-10 days), shortened in hyperthyroidism (3-4 days); clinical steady-state after 6-8 weeks of consistent dosing.
Approximately 1-2 days in euthyroid patients; shorter in hyperthyroidism, prolonged in hypothyroidism. Clinical context: requires monitoring of thyroid function tests for dose adjustment.
Renal (30-50% as unchanged drug and conjugates); fecal (biliary, 20-40% as conjugates); total clearance approximates 1-2 L/day in euthyroid patients.
Primarily renal (approximately 50% as unchanged drug and metabolites); minor biliary/fecal elimination.
Category C
Category A/B
Thyroid Hormone
Thyroid Hormone